Findings from the TRACE RA trial suggest that atorvastatin has a favorable safety profile and may reduce low-density lipoprotein cholesterol levels in patients with rheumatoid arthritis.
Rheumatoid arthritis flare rates are similar regardless of which drug type is tapered first after achievement of disease control during conventional synthetic DMARD and tumor necrosis factor inhibitor combination therapy, research shows.
Findings from a systematic review suggest that sexual dysfunction is common among both men and women with inflammatory arthritis, highlighting the importance of including sexual health in the routine management of rheumatic disease.
Levels of calprotectin in the synovial fluid can be used to discriminate patients with septic arthritis from those with pseudogout and rheumatoid arthritis, shows a report published in Rheumatology.
The decision to discontinue infliximab in ankylosing spondylitis patients who have achieved sustained remission “should be taken with considerable caution,” say Spanish researchers who found that over half relapsed after the tumor necrosis factor inhibitor was withdrawn.
The Janus kinase inhibitor tofacitinib has demonstrated a consistent safety profile and sustained efficacy in rheumatoid arthritis patients over a maximum follow-up of 9.5 years, report the ORAL Sequel investigators.
A panel of four soluble biomarkers comprising markers of cartilage metabolism, metabolic syndrome, and inflammation could distinguish psoriatic arthritis from osteoarthritis, researchers report.
A meta-analysis of 72 randomized controlled trials including 26,424 participants with knee osteoarthritis suggests that the beneficial pain-relief effects of oral NSAIDs peak at 2 weeks, while minor adverse events begin to appear at 4 weeks.
Osteoarthritis is associated with a similar disease burden to rheumatoid arthritis at the time of first presentation, despite traditionally being perceived as a milder condition, researchers report.
Individuals with rheumatoid arthritis (RA) and chronic obstructive pulmonary disease who are treated with abatacept do not have an elevated risk for adverse respiratory events relative to those given other biologics, real-world study results suggest.
Tocilizumab is associated with a lower risk for major adverse cardiovascular events than tumor necrosis factor inhibitors among patients with rheumatoid arthritis, whereas the use of conventional DMARDs may be linked to an elevated risk, researchers report.
Older age, female sex, and poor functional status are significant predictors of dyspnea on exertion among patients with rheumatoid arthritis, researchers report.
Adding sarilumab to methotrexate significantly improves the signs and symptoms of rheumatoid arthritis relative to placebo in Japanese patients with an inadequate response to methotrexate monotherapy, study findings indicate.
Individuals with systemic sclerosis have an elevated risk for ischemic stroke after adjustment for traditional cardiovascular risk factors, study findings suggest.
Treatment with biologics in combination with conventional DMARDs is associated with a reduction in the duration of protective immunity induced by the 17DD yellow fever vaccine among patients with rheumatoid arthritis, research suggests.